US Neurosurgical Holding (US Neurosurgical Holding) Interest Expense : $-0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is US Neurosurgical Holding Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. US Neurosurgical Holding's interest expense for the three months ended in Mar. 2024 was $ -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. US Neurosurgical Holding's Operating Income for the three months ended in Mar. 2024 was $ -0.48 Mil. US Neurosurgical Holding's Interest Expense for the three months ended in Mar. 2024 was $ -0.00 Mil. US Neurosurgical Holding did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

US Neurosurgical Holding Interest Expense Historical Data

The historical data trend for US Neurosurgical Holding's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US Neurosurgical Holding Interest Expense Chart

US Neurosurgical Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.09

-0.03

US Neurosurgical Holding Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

US Neurosurgical Holding Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

US Neurosurgical Holding (OTCPK:USNU) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

US Neurosurgical Holding's Interest Expense for the three months ended in Mar. 2024 was $-0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-0.48 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.05 Mil.

US Neurosurgical Holding's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

US Neurosurgical Holding did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

US Neurosurgical Holding (US Neurosurgical Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US Neurosurgical Holding Inc (OTCPK:USNU) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2400 Research Boulevard, Suite 325, Rockville, MD, USA, 20850

Website

http://www.usneuro.com

US Neurosurgical Holding Inc operates as a holding company in United State. It is a medical services company that partners with hospitals and physicians to operate facilities utilizing artistic and inventive technologies in medical treatment and diagnosis. It is engaged in providing medical treatment and diagnosis services that include stereotactic radiosurgery centers, utilizing gamma knife technology, and holds interests in radiological treatment facilities. The company is focusing on establishing cancer centers using intensity-modulated radiation therapy. Its gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery.

Executives

Lawrence William St	director	23 ASHLAND STREET, NEWBURYPORT MA 01950-1905
William F. Leimkuhler	director	43 SALEM STRAITS RD, DARIEN CT 06820
Merriman Charles H Iii	director
Alan Gold	director, 10 percent owner, officer: President & Chairman	2400 RESEARCH BLVD, SUITE 325, ROCKVILLE MD 20850
Stanley S Shuman	10 percent owner	C/O RIPPLEWOOD HOLDINGS LLC, ONE ROCKERFELLER PLAZA, NEW YORK NY 10020
Allen & Co Inc	10 percent owner	711 FIFTH AVENUE, NEW YORK NY 10022

US Neurosurgical Holding (US Neurosurgical Holding) Headlines

No Headlines